Exeter Clinical Research Facility
Exeter, Devon, EX25DW, United Kingdom
NCT Number: NCT02921906
Neonatal diabetes is diagnosed before 6 months of age and causes high blood glucose levels due to the pancreas not secreting insulin. Neonatal diabetes can be caused by a change in a DNA region called the KCNJ11 gene. KCNJ11 encodes a channel in the pancreas that acts as a switch to turn 'on' and 'off' insulin secretion. A change in KCNJ11 results in a faulty channel, which keeps insulin secretion 'switched off'. The diabetes can be treated with tablets called sulphonylureas that switch the pancreatic channel 'on', allowing it to secrete insulin in response to gut hormones called incretins. Previous research has shown that patients who switch from insulin to sulphonylureas have better blood glucose control, including fewer episodes of hypoglycaemia (glucose dropping too low), and also avoid the need for injections. It is thought that serious side effects from sulphonylureas are uncommon in KCNJ11 neonatal diabetes. Some patients report low glucose after meals and we think this may be because they make too much insulin if they eat a meal with protein but low amounts of carbohydrate. The investigators will test this by giving study participants different meals and measuring the amount of insulin, glucose and incretin hormone in the blood afterwards.
Looking for future studies?
Notify Me8 year and older
All sexes
Interventional
Not applicable
Exeter, Devon, EX25DW, United Kingdom
Anecdotal evidence from routine clinical care suggests that patients with sulphonylurea-treated KCNJ11 neonatal diabetes, when they eat, may experience mild hypoglycaemia if the food consumed lacks carbohydrate. It has been suggested that this may be due to regulation of insulin secretion via the incretin pathway as opposed to the classical ATP pathway. Therefore the investigators hypothesise that foods with a relatively high protein content compared to those with a relatively high carbohydrate content will result in excessive insulin secretion and relatively lower glucose values in KCNJ11 patients. This would be in contrast to healthy control subjects or subjects with SU-treated T2D where the insulin secretion will be moderated by the ambient glucose via the classical ATP pathway. The investigators will formally study this hypothesis by comparing the insulin, glucose and incretin hormone responses to a high protein meal with a high carbohydrate meal in people with KCNJ11 neonatal diabetes, people without diabetes and people with sulphonylurea-treated Type 2 Diabetes. To assess whether any effect seen is due to direct stimulation of the beta cell by the sulphonylurea itself, people with KCNJ11 neonatal diabetes will also undergo the same tests in the fasting state, having taken the sulphonylurea in the absence of any food.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Breakfast with high protein / low carbohydrate content
Breakfast with high carbohydrate / low protein content
Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.
Other names: Acetaminophen
People with diabetes take sulphonylurea medication in the absence of any food stimulus
Time frame: 240 minutes
Glucose AUC after each meal.
Time frame: 240 minutes
Insulin AUC after each meal.
Time frame: 240 minutes
GLP-1 AUC after each meal.
Time frame: 240 minutes
GIP AUC after each meal.
Time frame: 240 minutes
Glucagon AUC after each meal.
Time frame: 240 minutes
Rate of change of paracetamol levels after each meal as marker of gastric emptying.
Royal Devon and Exeter NHS Foundation Trust
Other
Assessing the Effect of Food Composition on Postprandial Insulin Secretion in KCNJ11 Neonatal Diabetes (FoND Study)
Acronym: FoND
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04831723
Neonatal Diabetes
Dorchester, United Kingdom
View Trial DetailsNCT07492004
Diabetes Mellitus, Diabetes Mellitus, Type 2
Tianjin, China
View Trial DetailsNCT03988764
Abnormalities, Multiple, Autoimmune Diseases
Montreal, Quebec, Canada
View Trial DetailsNCT07618663
Diabetes Mellitus, Endocrine System Diseases
Lahore, Shaikhupura, Pakistan
View Trial Details